(Q35178065)

7 August 2017

Influence of pharmacogenetic variability on the pharmacokinetics and toxicity of the aurora kinase inhibitor danusertib (English)

1 reference

7 August 2017

1 reference

11

Henk-Jan Guchelaar

1 reference

7 August 2017

10

Hans Gelderblom

1 reference

7 August 2017

2

Ron H J Mathijssen

1 reference

Tahar R. J. H. M. van der Straaten

7 August 2017

5

object named as

Tahar van der Straaten

1 reference

7 August 2017

3

Judith A M Wessels

1 reference

7 August 2017

1

Neeltje Steeghs

1 reference

7 August 2017

4

Anne-Joy de Graan

1 reference

7 August 2017

Mariangela Mariani

6

1 reference

7 August 2017

Bernard Laffranchi

7

1 reference

7 August 2017

Silvia Comis

8

1 reference

7 August 2017

Maja J A de Jonge

9

1 reference

7 August 2017

25 February 2010

1 reference

Investigational New Drugs

7 August 2017

1 reference

7 August 2017

29

1 reference

7 August 2017

5

1 reference

7 August 2017

953-962

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9405-7

7 August 2017

0 references

cites work

Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

PLINK: a tool set for whole-genome association and population-based linkage analyses

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Translating pharmacogenomics: challenges on the road to the clinic

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Aurora kinases: new targets for cancer therapy

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Tubulin-associated drug targets: Aurora kinases, Polo-like kinases, and others

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development.

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Dihydropyrimidine dehydrogenase pharmacogenetics in patients with colorectal cancer

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Building population pharmacokineticpharmacodynamic models. I. Models for covariate effects

13 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

Phase I pharmacokinetic and pharmacodynamic study of the aurora kinase inhibitor danusertib in patients with advanced or metastatic solid tumors

13 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-010-9405-7

UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS10637-010-9405-7

Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3160560

10.1007/S10637-010-9405-7

27 September 2018

Identifiers

DOI

1 reference

7 August 2017

1 reference

7 August 2017

1 reference